Cuba encouraged by early efficacy results of COVID-19 vaccine

Cuba’s Soberana 2 vaccine candidate shows 62 percent efficacy with two of its three doses in trials, says BioCubaFarma.

Cuba’s Soberana 2 vaccine candidate has shown 62 percent efficacy with just two of its three doses, state-run biopharmaceutical corporation BioCubaFarma has said, citing preliminary data from late phase trials. Cuba, whose biotech sector has exported vaccines for decades, has five vaccine candidates in clinical trials, of which two – Soberana 2 and Abdala – are in late phase trials. “In a few weeks we should have the results for the efficacy with three doses which we expect will be superior,” said Vicente Vérez​, director of the state-run Finlay Vaccine Institute, which developed Soberana 2.